drugset / Trial / NCT04981691
Anti-mesothelin CAR-T Cells With Advanced Refractory Solid Tumors
NaSingle-groupOpen-labelTreatment
Summary
The goal of this clinical trial is to study the safety, efficacy, and pharmacokinetics of mRNA-engineered anti-Mesothelin (MESO) Chimeric Antigen Receptor T-Cell (CAR-T cells) therapy in patients with mesothelin expression-positive, advanced solid tumors that have failed at least first-line or second-line therapy.
Timeline
- Start
- 2021-10-01
- Primary completion
- 2022-01-09
- Completion
- 2022-07-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | anti-MESO CAR-T cells | Cell therapy | 1e+09 cells | Intravenous |
| Subject | anti-MESO CAR-T cells | Cell therapy | 3e+09 cells | Intravenous |